DABIGATRAN (Evidence from RELY & RELYABLE Trial) & Novel Oral Anticoagulants (NOAC) Dr. Surinder Hansra MD, DNB (Card) FSCAI AF & Stroke • AF increases the…

Slide 1Nuovi farmaci antitrombotici: che cosa cambierà in clinica nei prossimi anni? GF Gensini Livorno 27 marzo 2004 Slide 2 Currently available anticoagulants: largely…

1. ACC 2013What did we learn 2. • Vinod H. Thourani, MD, of Emory University (Atlanta, GA),presented 3-year data from cohort A of the PARTNER(Placement of AoRTic traNscatheterER…

Slide 1LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE Slide 2 STROKE Rate in patients not taking warfarin, in AF 5.00 / year 1.0 - 7.0…

Slide 1 I.V. Enoxaparin or Unfractionated Heparin in Primary PCI: Acute and Long-term results G. M ONTALESCOT, DISCLOSURE : Research Grants to the Institution or Consulting/Lecture…

Slide 1 Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Slide 2 Starting Point Low Molecular Weight Heparin (LMWH): Inhibits…

Slide 1 Improving the Outcomes of Oral Anticoagulation: Home Monitoring of Warfarin Therapy Jack Ansell, M.D. Lenox Hill Hospital, NY September 22, 2009 Disclosures Consultant:…

Slide 1 Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine Chief…

PowerPoint Presentation Antiplatelet Therapy CHAMPION PHOENIX: Primary Efficacy Outcomes at 48 Hours, MITT TRITON-TIMI 38 13,608 Patients With ACS and Planned PCI Randomized…

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group 9 611 - 10/06/11 Background of The Study Sponsor: Bayer Schering Pharma & Ortho McNeil Objectives: To compare…